Compare HLN & LVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLN | LVS |
|---|---|---|
| Founded | 2022 | 1988 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Hotels/Resorts |
| Sector | Consumer Discretionary | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.7B | 45.5B |
| IPO Year | N/A | 2004 |
| Metric | HLN | LVS |
|---|---|---|
| Price | $10.15 | $66.39 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 14 |
| Target Price | N/A | ★ $67.21 |
| AVG Volume (30 Days) | ★ 10.1M | 4.8M |
| Earning Date | 07-31-2025 | 01-28-2026 |
| Dividend Yield | ★ 1.79% | 1.51% |
| EPS Growth | ★ 41.64 | 9.73 |
| EPS | 0.23 | ★ 2.22 |
| Revenue | ★ $15,096,588,575.00 | $12,264,000,000.00 |
| Revenue This Year | $1.51 | $13.03 |
| Revenue Next Year | $4.67 | $5.64 |
| P/E Ratio | ★ $21.47 | $29.88 |
| Revenue Growth | N/A | ★ 8.37 |
| 52 Week Low | $8.71 | $30.18 |
| 52 Week High | $11.42 | $70.46 |
| Indicator | HLN | LVS |
|---|---|---|
| Relative Strength Index (RSI) | 66.93 | 54.01 |
| Support Level | $9.82 | $65.78 |
| Resistance Level | $9.65 | $67.64 |
| Average True Range (ATR) | 0.13 | 1.19 |
| MACD | 0.05 | -0.34 |
| Stochastic Oscillator | 97.09 | 50.00 |
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner Macao, Four Seasons Hotel Macao, and Parisian Macao, as well as the Marina Bay Sands resort in Singapore. We expect Sands to open a fourth tower in Singapore in 2031. Its Venetian and Palazzo Las Vegas assets in the US were sold to Apollo and Vici in 2022. After the sale of its Vegas assets, the company generates all its EBITDA from Asia, with its casino operations generating the majority of sales.